By Lina carolina 
Researchers at the Karolinska Institutet and the Astrid Lindgren Children’s Hospital in Sweden have made a groundbreaking discovery, illuminating the intricate ways children’s immune systems confront different types of cancer based on their age. This pivotal study, published in the esteemed journal Cell, reveals significant disparities in immune responses between pediatric and adult cancer patients, paving the way for the development of novel, tailored therapeutic strategies specifically designed for children battling cancer.
A New Frontier in Precision Medicine for Pediatric Oncology
The comprehensive study involved a cohort of 191 children, ranging in age from newborns to 18 years old, all diagnosed with various forms of solid tumors at the Astrid Lindgren Children’s Hospital between 2018 and 2024. The research team meticulously analyzed both tumor tissue and blood samples from these young patients. Their investigation focused on identifying genetic mutations within the tumors and, crucially, on discerning the activity or inactivity of specific genes within the immune system. This dual approach allowed for an unprecedented understanding of the interplay between a child’s developing immune system and the cancerous growths it faces.
Professor Petter Brodin, a leading figure in pediatric immunology at the Department of Women’s and Children’s Health at Karolinska Institutet and a practicing pediatrician at the Astrid Lindgren Children’s Hospital, emphasized the fundamental importance of immune system activation in the fight against cancer. "The activation of the immune system is crucial to our ability to fight cancer, but differs between children and adults," Professor Brodin stated. "If we’re to properly treat childhood cancer, we need to find out how the child’s immune system is activated and regulated in children with cancer and what factors affect their immune responses."
The study’s findings introduce a profound new dimension to the concept of precision medicine. Historically, precision medicine in oncology has predominantly centered on the intrinsic properties of the tumor itself, such as its genetic makeup and growth patterns. However, Professor Brodin elaborated on the study’s transformative implications: "Precision medicine in cancer has mostly focused on the tumour properties. By characterising the immune system, we’re introducing an entirely new dimension that will be instrumental in shaping the future of childhood cancer therapy." This shift in focus acknowledges that the body’s own defense mechanisms play an equally critical, and often distinct, role in how cancer develops and responds to treatment in children compared to adults.
Unraveling Age-Related Immune System Differences
A central revelation of the research is the distinct manner in which children’s and adults’ immune systems engage with cancer. The study unequivocally demonstrated that these responses are not uniform and that different types of tumors elicit varying degrees of immune system activation. This finding challenges the long-held assumption that immune responses to cancer are largely universal across age groups.
Professor Brodin further explained the observed differences: "What we can see is that children’s tumours are generally less inflammatory and have fewer mutations, which means that they likely appear less foreign to the immune system and that the immune system therefore doesn’t attack the tumours as forcefully." This observation suggests a fundamental biological divergence: tumors in younger individuals may present fewer "red flags" to a developing immune system, leading to a less aggressive counter-attack.
However, the researchers were quick to highlight the significant individual variability within the pediatric cohort. "Having said this, there are large individual variations, which underlines the importance of precision medicine, which is to say the adapting of treatment to individual patients," Professor Brodin stressed. "Our study shows how this can be done in practice." This variability underscores that even within the pediatric population, a one-size-fits-all approach to treatment is inadequate. The study provides the foundational data to move towards highly personalized treatment plans, acknowledging that each child’s immune landscape is unique.
Implications for Immunotherapy in Children
The study’s findings offer a compelling explanation for why certain highly effective immunotherapeutic treatments, such as checkpoint inhibitors, have shown limited success in pediatric cancer patients. Checkpoint inhibitors function by releasing the brakes on immune cells, allowing them to more effectively target and destroy tumor cells. This therapeutic modality relies heavily on the immune system already being primed and activated against the cancer.
"This requires the immune cells to be activated against the tumour," Professor Brodin explained. "We show that the child’s immune cells are often initially not activated against the tumour, which means that checkpoint inhibitors won’t work." This crucial insight suggests that the underlying immune environment in children with cancer is fundamentally different from that in adults, making these specific therapies less suitable.
The research proposes a new direction for pediatric immunotherapy: "Children likely need different types of immunotherapies that are more focused on triggering the immune cells to attack the tumour cells from scratch." This indicates a need for therapeutic strategies that actively stimulate and educate the child’s immune system to recognize and eliminate cancer cells, rather than simply releasing existing inhibitory signals. This could involve novel approaches that enhance antigen presentation, promote T-cell priming, or utilize different immune cell populations altogether.
Real-Time Monitoring of Immune Response for Treatment Guidance
A particularly innovative aspect of the study involved tracking the immune response over time and during treatment in a subset of the participating children. By doing so, the researchers were able to quantify changes in the population of killer T cells – the specialized immune cells responsible for directly eliminating tumor cells. This real-time monitoring capability has immediate clinical potential.
"This is something that we could make clinical use of today to judge the therapeutic effect and adjust the treatment to every individual patient," Professor Brodin stated, highlighting the practical applications of their findings. "We’ll now be testing this on a larger scale as we believe that it can be a useful complement to the genetic analyses of tumours that are already being done in routine care."
The ability to monitor the immune response in real-time offers a dynamic feedback mechanism for oncologists. It allows for an assessment of how well the chosen therapy is stimulating the child’s immune system to fight the cancer. If the immune response is not as robust as desired, treatments can be adjusted accordingly, potentially leading to better outcomes and minimizing exposure to ineffective or overly toxic therapies. This approach promises to augment existing diagnostic tools, such as tumor genetic profiling, by providing a crucial immunological perspective.
The Road Ahead: Collaboration and Future Research
The groundbreaking study was a collaborative effort, led by Professor Petter Brodin and Linda Ljungblad, an oncology resident and researcher at Karolinska Institutet. The research was conducted in close partnership with the pediatric oncology clinic at the Astrid Lindgren Children’s Hospital, a renowned center for childhood cancer care. This seamless integration between cutting-edge research and clinical practice is a testament to Sweden’s commitment to advancing pediatric oncology.
The project received substantial financial backing from a consortium of influential organizations dedicated to cancer research and child welfare, including the Swedish Cancer Society, the Swedish Childhood Cancer Foundation, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, and Karolinska Institutet. This broad financial support underscores the recognized importance and potential impact of the research.
It is also noteworthy that Professor Brodin and several other co-authors are co-founders of Cytodelics AB, a company likely involved in developing or applying technologies related to cellular and molecular analysis. Furthermore, Professor Brodin holds positions on the executive board of Kancera AB and serves as a scientific advisor to several other innovative biotechnology and health companies, including Pixelgen Technologies AB, Sention Health AB, Helaina Inc, Scailyte AG, and Oxford Immune Algorithmics. These affiliations suggest a strong commitment to translating scientific discoveries into tangible clinical advancements.
The implications of this research extend far beyond the immediate findings. By providing a deeper understanding of the pediatric immune system’s unique interactions with cancer, the study lays the groundwork for a paradigm shift in how childhood cancers are diagnosed, treated, and monitored. The development of age-specific immunotherapies and real-time immune response monitoring tools could significantly improve the efficacy of treatments, reduce the long-term side effects associated with current therapies, and ultimately enhance the survival rates and quality of life for children battling cancer. This work represents a significant leap forward in the quest for more effective and compassionate cancer care for the youngest and most vulnerable patients.